MSI cancer

I was part of a study initiated by our collaboration partners at ATB to explore new ways of cancer prevention and therapies. Together, we developed and used a novel algorithm, which quantitatively evaluates the mutations in MSI tumor cells. We could also show for the first time that the immune system monitors the tumor during its development and immediately eliminates cancer cells with highly immunogenic neoantigens. strongly supports the hypothesis that immunogenic cancer cell clones may be attacked and potentially eradicated by the host’s immune system and encourages the concept of cancer-preventive vaccines that may in the future help to reduce MSI tumor risk. The study was recently published in Nature Communications.